Published in J Clin Microbiol on June 01, 2003
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 2.90
Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 2.42
Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. Am J Respir Crit Care Med (2007) 2.05
Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol (2009) 2.05
Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol (2005) 1.76
Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol (2006) 1.75
Infectious disease, the innate immune response, and fibrosis. J Clin Invest (2007) 1.68
Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med (2008) 1.53
Retracted Innate immune activation by inhaled lipopolysaccharide, independent of oxidative stress, exacerbates silica-induced pulmonary fibrosis in mice. PLoS One (2012) 1.41
Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol (2013) 1.31
Interstitial lung diseases in children. Orphanet J Rare Dis (2010) 1.28
Twist: a regulator of epithelial-mesenchymal transition in lung fibrosis. PLoS One (2009) 1.26
Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor protein-3 complex disease. Mol Med (2012) 1.26
Latent herpesvirus infection augments experimental pulmonary fibrosis. Am J Respir Crit Care Med (2009) 1.25
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Model Mech (2013) 1.21
TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med (2010) 1.21
Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology (2009) 1.16
Fibrosis: ultimate and proximate causes. J Clin Invest (2014) 1.15
Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis. Am J Respir Cell Mol Biol (2012) 1.14
Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair (2008) 1.13
Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med (2005) 1.13
Signaling pathways in the epithelial origins of pulmonary fibrosis. Cell Cycle (2010) 1.10
Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med (2015) 1.04
New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs (2011) 1.03
Toll-like receptors, Notch ligands, and cytokines drive the chronicity of lung inflammation. Proc Am Thorac Soc (2007) 1.03
Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med (2010) 0.99
Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis. Am J Physiol Cell Physiol (2014) 0.98
Detection of viruses in human adenoid tissues by use of multiplex PCR. J Clin Microbiol (2008) 0.97
Workshop on idiopathic pulmonary fibrosis in older adults. Chest (2010) 0.96
TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol (2008) 0.96
CXCR2 is critical for dsRNA-induced lung injury: relevance to viral lung infection. J Inflamm (Lond) (2005) 0.96
Macrophage dysfunction and susceptibility to pulmonary Pseudomonas aeruginosa infection in surfactant protein C-deficient mice. J Immunol (2008) 0.96
The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol (2011) 0.96
Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci (2012) 0.95
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2015) 0.95
Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation. Ann Am Thorac Soc (2015) 0.95
Pulmonary fibrosis induced by γ-herpesvirus in aged mice is associated with increased fibroblast responsiveness to transforming growth factor-β. J Gerontol A Biol Sci Med Sci (2011) 0.94
Latent infection by γherpesvirus stimulates profibrotic mediator release from multiple cell types. Am J Physiol Lung Cell Mol Physiol (2010) 0.94
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther (2012) 0.93
The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--β1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells. Am J Respir Cell Mol Biol (2010) 0.92
Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology (2011) 0.91
Macrophage-mediated inflammation and disease: a focus on the lung. Mediators Inflamm (2012) 0.91
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis. Am J Pathol (2010) 0.88
Right place, right time: the evolving role of herpesvirus infection as a "second hit" in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2011) 0.87
The UPR and lung disease. Semin Immunopathol (2013) 0.86
Exacerbation of lung radiation injury by viral infection: the role of Clara cells and Clara cell secretory protein. Radiat Res (2013) 0.86
Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study. Pulm Med (2011) 0.85
Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. PLoS One (2011) 0.85
Human herpesvirus 8 and pulmonary hypertension. Emerg Infect Dis (2005) 0.85
γ-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates established murine lung fibrosis. Am J Physiol Lung Cell Mol Physiol (2014) 0.84
Modulation of lung inflammation by the Epstein-Barr virus protein Zta. Am J Physiol Lung Cell Mol Physiol (2010) 0.84
Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiol Rev (2016) 0.84
Lost after translation: insights from pulmonary surfactant for understanding the role of alveolar epithelial dysfunction and cellular quality control in fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol (2015) 0.83
Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study. Fibrogenesis Tissue Repair (2010) 0.83
Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. Mod Pathol (2013) 0.83
Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med (2013) 0.83
Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. PLoS One (2011) 0.83
Herpes virus infection is associated with vascular remodeling and pulmonary hypertension in idiopathic pulmonary fibrosis. PLoS One (2013) 0.83
Gastroesophageal reflux and idiopathic pulmonary fibrosis: a review. Pulm Med (2010) 0.83
Resistant pathogens, fungi, and viruses. Surg Clin North Am (2014) 0.82
Mycobacterial pulmonary infections in patients with idiopathic pulmonary fibrosis. J Korean Med Sci (2012) 0.82
Experimental induction of pulmonary fibrosis in horses with the gammaherpesvirus equine herpesvirus 5. PLoS One (2013) 0.81
TLR9-induced interferon β is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis. Fibrogenesis Tissue Repair (2011) 0.81
BK and JC polyomaviruses are not associated with idiopathic pulmonary fibrosis. J Clin Microbiol (2005) 0.79
The Role of Aging in Idiopathic Pulmonary Fibrosis. Lung (2015) 0.78
The anti-fibrotic effect of inhibition of TGFβ-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent γ-herpesvirus infection. Dis Model Mech (2015) 0.78
Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis. Biomed Res Int (2013) 0.78
Nanoparticle exposure reactivates latent herpesvirus and restores a signature of acute infection. Part Fibre Toxicol (2017) 0.77
Gammaherpesvirus-induced lung pathology is altered in the absence of macrophages. Lung (2005) 0.77
Following the path of CCL2 from prostaglandins to periostin in lung fibrosis. Am J Respir Cell Mol Biol (2014) 0.77
Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood. BMC Genomics (2014) 0.76
Pulmonary research in 2013 and beyond: a National Heart, Lung, and Blood Institute perspective. Am J Physiol Lung Cell Mol Physiol (2012) 0.76
TLR9 expression is required for the development of cigarette smoke-induced emphysema in mice. Am J Physiol Lung Cell Mol Physiol (2016) 0.76
Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genet (2016) 0.76
CD8+ T Cell Response to Gammaherpesvirus Infection Mediates Inflammation and Fibrosis in Interferon Gamma Receptor-Deficient Mice. PLoS One (2015) 0.76
Endemic Viruses of Squirrel Monkeys (Saimiri spp.). Comp Med (2015) 0.75
A first glimpse at the early origins of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2015) 0.75
The biology of the ABCA3 lipid transporter in lung health and disease. Cell Tissue Res (2016) 0.75
Stress in the ER (endoplasmic reticulum): a matter of life and death for epithelial cells. Am J Respir Crit Care Med (2008) 0.75
Microbiome in interstitial lung disease: from pathogenesis to treatment target. Curr Opin Pulm Med (2017) 0.75
Role of Microbial Agents in Pulmonary Fibrosis . Yale J Biol Med (2017) 0.75
The respiratory microbiome in idiopathic pulmonary fibrosis. Ann Transl Med (2017) 0.75
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene (1990) 10.41
Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med (1995) 8.52
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med (1998) 6.22
Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (1988) 4.90
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol (1997) 3.67
Familial fibrocystic pulmonary dysplasia and its relation to Hamman-Rich syndrome. Pediatrics (1959) 2.96
Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax (2000) 2.16
Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J (1997) 2.13
Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc (1998) 2.04
Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax (1995) 2.04
Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. Proc Natl Acad Sci U S A (1992) 1.85
The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1999) 1.71
Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol (2003) 1.64
Comparative evaluation of colorimetric microtiter plate systems for detection of herpes simplex virus in cerebrospinal fluid. J Clin Microbiol (1998) 1.49
Prevalence of antibody to human herpesvirus 7 by age. J Infect Dis (1993) 1.36
Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association? Lancet (1984) 1.35
Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis (1992) 1.32
A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2002) 1.29
Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax (2000) 1.23
Molecular evidence and clinical significance of herpesvirus coinfection in the central nervous system. J Clin Microbiol (1997) 1.23
Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol (1999) 1.14
Three new human herpesviruses (HHV6, 7, and 8). Lancet (1997) 1.13
Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J (1997) 1.09
Viruses and idiopathic pulmonary fibrosis. Eur Respir J (1997) 1.05
Epstein-Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis. J Clin Invest (1999) 1.05
The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). N Engl J Med (2000) 1.01
"Cytomegalovirus disease" in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? J Med Virol (1996) 1.01
Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax (1996) 0.98
Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med (1995) 0.94
Viruses and idiopathic pulmonary fibrosis. Monaldi Arch Chest Dis (2000) 0.94
Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med (2007) 8.23
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis (2007) 5.51
Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med (2002) 4.66
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol (2005) 4.57
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86
Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A (2008) 3.86
Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. N Engl J Med (2011) 3.58
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis (2011) 3.19
Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Primary pulmonary hypertension. Lancet (2003) 3.08
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol (2007) 2.88
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine (2007) 2.68
The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med (2007) 2.62
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol (2011) 2.53
The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol (2006) 2.43
Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol (2008) 2.39
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am J Respir Crit Care Med (2005) 2.33
Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.31
MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med (2013) 2.31
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One (2010) 2.24
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem (2004) 2.24
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis (2002) 2.19
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med (2002) 2.17
Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet (2012) 2.16
Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med (2004) 2.10
Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood (2011) 2.08
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
The role of IFN in respiratory syncytial virus pathogenesis. J Immunol (2002) 1.95
Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses. Am J Physiol Lung Cell Mol Physiol (2004) 1.91
Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol (2010) 1.89
Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation (2005) 1.82
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol (2010) 1.81
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.81
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis (2010) 1.79
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One (2010) 1.71
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine (2006) 1.71
Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol (2004) 1.64
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation (2002) 1.62
Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res (2005) 1.61
Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol (2007) 1.61
Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum Mutat (2009) 1.60
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology (2009) 1.58
Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J Biol Chem (2003) 1.57
Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol (2005) 1.56
NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol (2002) 1.55
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem (2002) 1.54
Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Natl Acad Sci U S A (2002) 1.54
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One (2010) 1.53
Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol (2004) 1.53
Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levels. J Allergy Clin Immunol (2005) 1.52
Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. N Engl J Med (2015) 1.51
Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol (2009) 1.51
The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. J Virol (2005) 1.50
Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension. Genet Med (2008) 1.49
Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med (2005) 1.45
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis (2013) 1.45
Subunit recombinant vaccine protects against monkeypox. J Immunol (2006) 1.44
Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med (2008) 1.42
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis (2011) 1.42
Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc (2005) 1.42
Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med (2002) 1.40
Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. J Infect Dis (2005) 1.40
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine (2008) 1.39
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011) 1.39
Racial/ethnic differences in adults in randomized clinical trials of binge eating disorder. J Consult Clin Psychol (2011) 1.38
Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol (2010) 1.38
Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol (2004) 1.38
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest (2012) 1.37
RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology. J Virol (2005) 1.36
Blood-informative transcripts define nine common axes of peripheral blood gene expression. PLoS Genet (2013) 1.36
Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis (2004) 1.36
Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc Natl Acad Sci U S A (2010) 1.35
Ventricular geometry, strain, and rotational mechanics in pulmonary hypertension. Circulation (2010) 1.34
Smallpox vaccines: Past, present, and future. J Allergy Clin Immunol (2006) 1.33
Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation. J Virol (2003) 1.33